- Home
- CGON vs LGND Comparison
CGON vs LGND Comparison
Compare CGON & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGON
- LGND
- Stock Information
- Founded
- CGON 2010
- LGND 1987
- Country
- CGON United States
- LGND United States
- Employees
- CGON N/A
- LGND 68
- Industry
- CGON
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- CGON
- LGND Health Care
- Exchange
- CGON NYSE
- LGND Nasdaq
- Market Cap
- CGON 2.0B
- LGND 2.2B
- IPO Year
- CGON 2024
- LGND 1992
- Fundamental
- Price
- CGON $26.91
- LGND $135.23
- Analyst Decision
- CGON Strong Buy
- LGND Strong Buy
- Analyst Count
- CGON 11
- LGND 8
- Target Price
- CGON $63.30
- LGND $144.71
- AVG Volume (30 Days)
- CGON 979.0K
- LGND 139.7K
- Earning Date
- CGON 08-07-2025
- LGND 08-05-2025
- Dividend Yield
- CGON N/A
- LGND N/A
- EPS Growth
- CGON N/A
- LGND N/A
- EPS
- CGON N/A
- LGND N/A
- Revenue
- CGON $662,000.00
- LGND $181,488,000.00
- Revenue This Year
- CGON N/A
- LGND $18.41
- Revenue Next Year
- CGON $21,843.29
- LGND $18.87
- P/E Ratio
- CGON N/A
- LGND N/A
- Revenue Growth
- CGON 224.51
- LGND 53.40
- 52 Week Low
- CGON $14.80
- LGND $81.74
- 52 Week High
- CGON $40.47
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- CGON 54.12
- LGND 60.93
- Support Level
- CGON $25.14
- LGND $131.57
- Resistance Level
- CGON $27.09
- LGND $143.13
- Average True Range (ATR)
- CGON 1.50
- LGND 5.28
- MACD
- CGON -0.04
- LGND -0.22
- Stochastic Oscillator
- CGON 53.56
- LGND 64.81
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.